Study of a new drug for agitation in Alzheimer's disease
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This study tests an experimental medication, ITI-1284, to see if it can safely reduce agitation in people with Alzheimer's disease. Agitation can include restlessness, aggression, or irritability, and this drug aims to help manage those symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of Alzheimer's disease, confirmed by a blood test or a previous brain scan or spinal fluid test.
- You experience agitation that is not caused by other medications, medical conditions, or substance use.
- Your agitation is significant enough to score at least 4 on a standard assessment (NPI-AA) at two visits.
- Your overall dementia severity is moderate, as measured by a score between 6 and 24 on the MMSE-2 test.
- You do not have other major psychiatric conditions like schizophrenia, bipolar disorder, or unstable depression.
- You are not at high risk of suicide and have not attempted suicide in the past two years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether electroacupuncture (acupuncture with a gentle electric current) can help calm agitation in people with Alzheimer's disease. If you or a loved one has Alzheimer's and struggles with restlessness or aggression, this treatment might offer a drug-free option.
This trial tests an experimental medication to reduce hallucinations and delusions in people who have Alzheimer's disease. It may help manage these symptoms and improve quality of life for patients and their caregivers.
This trial tests two new drugs (EXV-802 and EXV-801) to see if they can safely reduce moderate to severe agitation in people with Alzheimer's dementia. If you or a loved one has Alzheimer's and has been experiencing significant agitation for at least two weeks, this study may be an option.
This trial tests a skin patch that delivers a medicine called dexmedetomidine to help calm agitation in people with Alzheimer's disease. It might be an option for those living in a care facility who have had recent episodes of agitation.
This early-stage trial tests whether ABBV-1758, a new drug given by injection, is safe and effective for people with Alzheimer's disease. The drug targets amyloid, a protein that builds up in the brains of people with Alzheimer's.
This trial tests an investigational drug called BMS-986368 to see if it can safely reduce agitation in people with Alzheimer's disease. You may be able to join if you have Alzheimer's with confirmed biomarkers and experience agitation that has been going on for at least 4 weeks.
Hear when a new Agitation Associated With Alzheimer's Dementia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.